Skip to main content

Table 2 Objective response in 41 patients

From: Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients

Responses

No. of patients

%

Complete response

2

5

Partial response

13

32

Stable disease

17

41

Progressive disease

9

22

Clinical Benefit

32

78

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us